

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method of inhibiting inflammation in an *in vitro* model for inflammation, the method comprising:

inhibiting integrin linked kinase (ILK) as set forth in SEQ ID NO:1 by contacting cells in said *in vitro* model with an effective dose of a compound that inhibits said integrin linked kinase (ILK), as set forth in SEQ ID NO:1 wherein inflammation is inhibited.

2-3. (canceled)

4. (previously presented) The method according to Claim 1, wherein said compound comprises a small organic molecule.

5. (original) The method according to Claim 4, wherein said molecule blocks ILK catalytic activity.

6. (previously presented) The method according to Claim 1, wherein said compound decreases the available level of [PtdIns (3,4,5) P<sub>3</sub>] in a cell.

7. (previously presented) The method according to Claim 6, wherein said compound is wortmannin.

8. (previously presented) The method according to Claim 6, wherein said compound is LY294002.

9. (original) The method of Claim 1, wherein cellular migration is inhibited.

10. (currently amended) A method of preventing inflammation in an *in vitro* model for inflammation, the method comprising:

inhibiting integrin linked kinase (ILK) as set forth in SEQ ID NO:1 by contacting said *in vitro* model with an effective dose of a compound that inhibits said integrin linked kinase (ILK), as set forth in SEQ ID NO:1, wherein inflammation is prevented.

USSN: 09/840,704

11-12. (canceled)

13. (previously presented) The method according to Claim 10, wherein said compound comprises a small organic molecule.

14. (original) The method according to Claim 13, wherein said molecule blocks ILK catalytic activity.

15. (previously presented) The method according to Claim 10, wherein said compound decreases the available level of [PtdIns (3,4,5) P<sub>3</sub>] in a cell.

16. (previously presented) The method according to Claim 15, wherein said compound is wortmannin.

17. (previously presented) The method according to Claim 15, wherein said compound is LY294002.

18. (original) The method of Claim 10, wherein cellular migration is inhibited.